Link Pharma Chem

Why is Link Pharma Chem Ltd falling/rising?

As of 29-Jun, Link Pharma Chem Ltd's stock price is rising to Rs 28.00, reflecting a 3.7% increase. This upward trend is supported by strong performance, increased investor participation, and trading above key moving averages, indicating positive short-term momentum.

As of 29-Jun, Link Pharma Chem Ltd's stock price is rising, currently at Rs 28.00, reflecting a change of 1.0 (3.7%) upward. This increase is supported by a strong performance today, where the stock outperformed its sector by 3.67% and has gained consecutively over the last two days, accumulating a total return of 7.4% during this period. The stock opened with a gain of 3.7% today and reached an intraday high of Rs 28, maintaining this price without fluctuation.<BR><BR>Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 83.5% compared to the 5-day average, indicating heightened interest in the stock. The stock is currently trading above its 5-day, 20-day, and 100-day moving averages, which suggests a positive short-term trend, although it remains below its 50-day and 200-day moving averages.<BR><BR>Overall, the combination of recent gains, increased trading volume, and positive performance relative to the sector contributes to the stock's upward movement.

Which are the latest news on Link Pharma Chem?

Should I buy, sell or hold Link Pharma Chem Ltd?

How big is Link Pharma Chem?

As of 10th June, Link Pharma Chem Ltd has a market capitalization of 12.00 Cr, with net sales of 27.42 Cr and a net profit of 0.08 Cr over the latest four quarters.

As of 10th June, Link Pharma Chem Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 27.42 Cr and a net profit of 0.08 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 12.66 Cr and total assets of 23.06 Cr.

Who are in the management team of Link Pharma Chem?

The management team of Link Pharma Chem consists of S G Thakur (Chairman & Wholetime Director), Rishikesh S. Thakur (Managing Director), and independent directors S B Dhatrak, Devang U Shah, and Rachna Ghai.

The management team of Link Pharma Chem includes the following individuals:<BR><BR>1. S G Thakur - Chairman & Wholetime Director<BR>2. Rishikesh S. Thakur - Managing Director<BR>3. S B Dhatrak - Independent Director<BR>4. Devang U Shah - Independent Director<BR>5. Rachna Ghai - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Link Pharma Chem?

Link Pharma Chem's peers include Square Four Pro., Vivid Global, Kobo Biotech, Sreechem Resins, Emmessar Biotech, Kuwer Industries, Lime Chemicals, Bhagawati Oxygen, and Padmanabh Inds. Link Pharma Chem has a Below Average management risk and a 1-year return of -27.83%.

Peers: The peers of Link Pharma Chem are Square Four Pro., Vivid Global, Kobo Biotech, Sreechem Resins, Emmessar Biotech, Kuwer Industries, Lime Chemicals, Bhagawati Oxygen, and Padmanabh Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Emmessar Biotech and the rest. Below Average management risk is noted at Vivid Global, Kuwer Industries, Link Pharma Chem, Lime Chemicals, and Padmanabh Inds. Growth is rated as Good for Sreechem Resins, Average for Padmanabh Inds, and Below Average for Vivid Global, Emmessar Biotech, Kuwer Industries, Link Pharma Chem, and Lime Chemicals. Capital Structure is rated as Good for Vivid Global, while Below Average is seen at Sreechem Resins, Emmessar Biotech, Kuwer Industries, Link Pharma Chem, Lime Chemicals, and Padmanabh Inds.<BR><BR>Return Snapshot: Kobo Biotech has the highest 1-year return at 134.11%, while Bhagawati Oxygen has the lowest at -37.07%. Link Pharma Chem's 1-year return is -27.83%, which is higher than Bhagawati Oxygen's but lower than Kobo Biotech's. Additionally, the six-month return is negative for Emmessar Biotech, Link Pharma Chem, Lime Chemicals, and Bhagawati Oxygen.

What does Link Pharma Chem do?

Link Pharma Chem Ltd is a mid-size chemical manufacturing company established in 1986, specializing in commodity chemicals with a current production capacity of 2100 tons per annum. As of March 2026, it reported net sales of 7 Cr and a market cap of INR 12 Cr.

Overview: <BR>Link Pharma Chem Ltd is a mid-size leading chemical manufacturing company operating in the commodity chemicals industry, categorized as a micro-cap.<BR><BR>History: <BR>Incorporated in 1986, Link Pharma Chem Ltd has undergone several expansions, increasing its production capacity from 300 tons per annum to 2100 tons per annum by 1994. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 12 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 153.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.50 <BR>Return on Equity: 0.61% <BR>Price to Book: 0.94 <BR><BR>Contact Details: <BR>Address: 162, GIDC Ind Estate Nandesari Vadodara Gujarat : 391340 <BR>Tel: 91-0265-3065000/2840448/3093931 <BR>Email: linkpharmacs@gmail.com <BR>Website: http://www.linkpharmachem.co.in

Are Link Pharma Chem Ltd latest results good or bad?

Link Pharma Chem Ltd's latest Q4 FY26 results are concerning, showing a net loss of ₹0.41 crores and declining revenues, with a significant drop in operating and profit margins. The company has faced two consecutive quarterly losses and its stock has decreased by 20.71% over the past year, indicating ongoing financial challenges.

Link Pharma Chem Ltd's latest results for Q4 FY26 indicate a challenging financial situation. The company reported a net loss of ₹0.41 crores, which is a deeper loss compared to the ₹0.35 crores loss in Q4 FY25. This marks the second consecutive quarterly loss, highlighting ongoing profitability issues.<BR><BR>Revenue for the quarter was ₹6.59 crores, showing a slight year-on-year increase of 2.17%, but a decline of 2.08% compared to the previous quarter. The operating margin fell to -3.49%, which is the lowest recorded for the company, reflecting significant operational instability. Additionally, the profit after tax (PAT) margin deteriorated to -6.22%, worse than the -5.43% margin from the same quarter last year.<BR><BR>Overall, the results suggest that Link Pharma Chem is facing serious operational challenges, with persistent losses and declining revenues indicating a troubling trend. The company's stock has also underperformed significantly, declining 20.71% over the past year, which further underscores investor concerns about its future prospects.

When is the next results date for Link Pharma Chem Ltd?

Link Pharma Chem Ltd will announce its results on 21 May 2026.

Link Pharma Chem Ltd is scheduled to declare its results on 21 May 2026.

How has been the historical performance of Link Pharma Chem?

Link Pharma Chem has experienced a significant decline in net sales and profitability, with losses reported in the most recent fiscal year. Net sales dropped from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, and the company reported a profit after tax loss of -1.03 Cr in March 2025.

Answer:<BR>The historical performance of Link Pharma Chem shows a declining trend in net sales and profitability over the past few years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Link Pharma Chem's net sales have decreased from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, reflecting a significant decline. The total operating income followed a similar trend, dropping from 53.56 Cr in March 2022 to 25.43 Cr in March 2025. The company's total expenditure also decreased, but not as sharply, leading to operating profits that turned negative in March 2024 and remained low at 0.31 Cr in March 2025. Profit before tax has been negative since March 2024, with a loss of 1.40 Cr reported in March 2025. Consequently, the profit after tax also showed losses, amounting to -1.03 Cr in March 2025. The company's total assets decreased from 32.46 Cr in March 2023 to 23.06 Cr in March 2025, while total liabilities also fell from 25.95 Cr to 23.06 Cr in the same period. Cash flow from operating activities was positive at 2.00 Cr in March 2025, but the overall cash position remained stagnant, with no cash inflow or outflow reported. Overall, Link Pharma Chem has faced significant challenges, leading to declining revenues and profitability over the years.

Is Link Pharma Chem overvalued or undervalued?

As of May 28, 2025, Link Pharma Chem is considered risky and overvalued with a negative PE ratio of -15.17 and a year-to-date return of -12.29%, significantly underperforming compared to its peers like Godrej Industries and the Sensex.

As of 28 May 2025, the valuation grade for Link Pharma Chem has moved from very attractive to risky. The company is currently assessed as overvalued, given its negative PE ratio of -15.17, an EV to EBITDA of 22.01, and a ROE of -7.51%. These ratios indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Link Pharma Chem's valuation metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a more favorable market position. Additionally, Solar Industries is deemed very expensive with a PE ratio of 123.77, highlighting the disparity in valuation within the sector. Despite a recent uptick in stock price, Link Pharma Chem's year-to-date return of -12.29% significantly underperforms the Sensex's 5.66%, reinforcing the notion of its overvaluation.

What is the technical trend for Link Pharma Chem?

As of June 5, 2025, Link Pharma Chem's trend has shifted to bearish, supported by bearish indicators from moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST.

As of 5 June 2025, the technical trend for Link Pharma Chem has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend. Both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages are also bearish, reinforcing the negative sentiment. The KST shows a mildly bullish signal on the weekly chart, but is bearish on the monthly, indicating mixed signals. Overall, the lack of clear trends in Dow Theory further supports a bearish perspective.

Who are the top shareholders of the Link Pharma Chem?

The top shareholders of Link Pharma Chem include Rishikesh Satishbhai Thakur with 18.95%, followed by Gurudev Marketing Pvt. Ltd. at 5.76%, and individual investors holding 37.17%. There are no pledged promoter holdings, minimal mutual fund involvement, and no foreign institutional investors.

The top shareholders of Link Pharma Chem include the promoters, with Rishikesh Satishbhai Thakur holding the largest share at 18.95%. The company has no pledged promoter holdings. In terms of public shareholders, Gurudev Marketing Pvt. Ltd. is the highest public shareholder with a stake of 5.76%. Additionally, individual investors collectively hold 37.17% of the shares. Mutual funds have a minimal presence, with only one scheme holding 0.02%, and there are currently no foreign institutional investors (FIIs) involved.

Has Link Pharma Chem declared dividend?

No Dividend History Available